Search

Your search keyword '"Smith, Eric L."' showing total 1,054 results
Start Over Author "Smith, Eric L."
1,054 results on '"Smith, Eric L."'

16. Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort study

Author

Korde, Neha, Tavitian, Elizabet, Mastey, Donna, Lengfellner, Joseph, Hevroni, Gil, Zarski, Andrew, Salcedo, Meghan, Mailankody, Sham, Hassoun, Hani, Smith, Eric L., Hultcrantz, Malin, Shah, Urvi, Tan, Carlyn, Diamond, Benjamin, Shah, Gunjan, Scordo, Michael, Lahoud, Oscar, Chung, David J., Landau, Heather, Giralt, Sergio, Derkach, Andriy, Atkinson, Thomas M., Sabbatini, Paul, König, Francesca, Usmani, Saad Z., Landgren, Ola, and Lesokhin, Alexander M.

Published
2023
Full Text
View/download PDF

17. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma

Author

Shah, Nina, Aiello, Jack, Avigan, David E, Berdeja, Jesus G, Borrello, Ivan M, Chari, Ajai, Cohen, Adam D, Ganapathi, Karthik, Gray, Lissa, Green, Damian, Krishnan, Amrita, Lin, Yi, Manasanch, Elisabet, Munshi, Nikhil C, Nooka, Ajay K, Rapoport, Aaron P, Smith, Eric L, Vij, Ravi, and Dhodapkar, Madhav

Subjects
Hematology, Immunization, Rare Diseases, Vaccine Related, Biotechnology, Cancer, Orphan Drug, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Consensus, Humans, Immunotherapy, Multiple Myeloma, guidelines as topic, immunotherapy, hematological neoplasms, receptors, chimeric antigen, antineoplastic protocols, receptors, chimeric antigen
Abstract

Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with the approval of new targeted agents and monoclonal antibodies directed against myeloma cell-surface antigens, as well as maturing data from late stage trials of chimeric antigen receptor CAR T cells. Therapies that engage the immune system to treat myeloma offer significant clinical benefits with durable responses and manageable toxicity profiles, however, the appropriate use of these immunotherapy agents can present unique challenges for practicing physicians. Therefore, the Society for Immunotherapy of Cancer convened an expert panel, which met to consider the current role of approved and emerging immunotherapy agents in MM and provide guidance to the oncology community by developing consensus recommendations. As immunotherapy evolves as a therapeutic option for the treatment of MM, these guidelines will be updated.

Published
2020

19. The Microbiome of Osteoarthritic Hip and Knee Joints: A Prospective Multicenter Investigation

Author

Goswami, Karan, Clarkson, Samuel, Tipton, Craig, Phillips, Caleb D., Dennis, Douglas A., Klatt, Brian A., O’Malley, Michael, Smith, Eric L., Gililland, Jeremy, Pelt, Christopher E., Peters, Christopher L., Malkani, Arthur L., Palumbo, Brian T., Lyons, Steven T., Bernasek, Thomas L., Minter, Jon, Goyal, Nitin, Purtill, William, McDonald, James F., III, Cross, Michael B., Prieto, Hernan A., Lee, Gwo-Chin, Hansen, Erik N., Bini, Stefano A., Ward, Derek T., Zhao, Neil, Shohat, Noam, Higuera, Carlos A., Nam, Dennis, Della Valle, Craig J., and Parvizi, Javad

Published
2023
Full Text
View/download PDF

25. Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma

Author

Holstein, Sarah A., Asimakopoulos, Fotis, Azab, Abdel Kareem, Bianchi, Giada, Bhutani, Manisha, Crews, Leslie A., Cupedo, Tom, Giles, Hannah, Gooding, Sarah, Hillengass, Jens, John, Lukas, Kaiser, Shari, Lee, Lydia, Maclachlan, Kylee, Pasquini, Marcelo C., Pichiorri, Flavia, Shah, Nina, Shokeen, Monica, Shy, Brian R., Smith, Eric L., Verona, Raluca, Usmani, Saad Z., and McCarthy, Philip L.

Published
2022
Full Text
View/download PDF

28. Similar incidence of postoperative sciatic nerve palsy in direct anterior and posterior approach total hip arthroplasty.

Author

Coden, Gloria S, Olsen, Aaron A, Schoeller, Lauren E, Niu, Ruijia, Pichiotino, Erin R, Freccero, David M, and Smith, Eric L

Subjects
PARALYSIS -- Risk factors, PARALYSIS treatment, RISK assessment, TOTAL hip replacement, SCIATIC nerve, T-test (Statistics), TREATMENT effectiveness, DESCRIPTIVE statistics, RETROSPECTIVE studies, MANN Whitney U Test, CHI-squared test, SURGICAL complications, ODDS ratio, DATA analysis software, CONFIDENCE intervals, PARALYSIS, DISEASE risk factors
Abstract

Background: Sciatic nerve palsy is a rare but devastating complication following total hip arthroplasty (THA). While the use of the direct anterior approach is increasing, limited data exist regarding sciatic nerve palsy and surgical approach. The purpose of this study was to determine the factors and outcomes associated with sciatic nerve palsy (SNP) after THA. Methods: A retrospective analysis was performed at a single institution of 7 SNP that occurred in 4045 THA via direct anterior approach and 10 SNP in 8854 THA via posterior approach, being operated between 01 January 2017 and 12 December 2021. SNP patients were matched 1:5 to patients without SNP. Medical records were reviewed for demographics including age, gender, body mass index (BMI), comorbidities, and preoperative indication. Additional workup of SNP patients including advanced imaging and reoperation were documented. Recovery grades were assigned to all SNP patients at most recent clinical follow-up. Results: 5 of the SNP were complete and 12 partial. They occurred as frequently with the direct anterior (0.17%) and posterior approach (0.11%, p = 0.5). The presence of femur cables and reoperations were associated with SNP (p = 0.04 and p = 0.002, respecitvely). Age, gender, BMI, comorbidities, and surgical indication had no effect on SNP. 4 of the 17 affected patients had almost complete recovery at latest follow-up. Conclusions: The incidence of SNP was similar in direct anterior and posterior approach. Surgeons should counsel patients regarding the risks of SNP regardless of the used approach. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial

Author

Diamond, Benjamin, Korde, Neha, Lesokhin, Alexander M, Smith, Eric L, Shah, Urvi, Mailankody, Sham, Hultcrantz, Malin, Hassoun, Hani, Lu, Sydney X, Tan, Carlyn, Rustad, Even H, Maura, Francesco, Maclachlan, Kylee, Peterson, Tim, Derkach, Andriy, Devlin, Sean, Landau, Heather J, Scordo, Michael, Chung, David J, Shah, Gunjan L, Lahoud, Oscar, Thoren, Katie, Murata, Kazunori, Ramanathan, Lakshmi, Arcila, Maria E, Ho, Caleb, Roshal, Mikhail, Dogan, Ahmet, Giralt, Sergio A, and Landgren, Ola

Published
2021
Full Text
View/download PDF

38. Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma

Author

Gomez-Arteaga, Alexandra, Shah, Gunjan L., Baser, Raymond E., Scordo, Michael, Ruiz, Josel D., Bryant, Adam, Dahi, Parastoo B., Ghosh, Arnab, Lahoud, Oscar B., Landau, Heather J., Landgren, Ola, Shaffer, Brian C., Smith, Eric L., Koehne, Guenther, Perales, Miguel-Angel, Giralt, Sergio A., and Chung, David J.

Published
2020
Full Text
View/download PDF

49. Data from Activation of Tumor-Cell STING Primes NK-Cell Therapy

Author

Knelson, Erik H., primary, Ivanova, Elena V., primary, Tarannum, Mubin, primary, Campisi, Marco, primary, Lizotte, Patrick H., primary, Booker, Matthew A., primary, Ozgenc, Ismail, primary, Noureddine, Moataz, primary, Meisenheimer, Brittany, primary, Chen, Minyue, primary, Piel, Brandon, primary, Spicer, Nathaniel, primary, Obua, Bonje, primary, Messier, Cameron M., primary, Shannon, Erin, primary, Mahadevan, Navin R., primary, Tani, Tetsuo, primary, Schol, Pieter J., primary, Lee-Hassett, Anna M., primary, Zlota, Ari, primary, Vo, Ha V., primary, Ha, Minh, primary, Bertram, Arrien A., primary, Han, Saemi, primary, Thai, Tran C., primary, Gustafson, Corinne E., primary, Venugopal, Kartika, primary, Haggerty, Timothy J., primary, Albertson, Thomas P., primary, Hartley, Antja-Voy, primary, Eser, Pinar O., primary, Li, Ze-Hua, primary, Cañadas, Israel, primary, Vivero, Marina, primary, De Rienzo, Assunta, primary, Richards, William G., primary, Abu-Yousif, Adnan O., primary, Appleman, Vicky A., primary, Gregory, Richard C., primary, Parent, Alexander, primary, Lineberry, Neil, primary, Smith, Eric L., primary, Jänne, Pasi A., primary, Miret, Juan J., primary, Tolstorukov, Michael Y., primary, Romee, Rizwan, primary, Paweletz, Cloud P., primary, Bueno, Raphael, primary, and Barbie, David A., primary

Published
2023
Full Text
View/download PDF

50. Data from BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy

Author

Smith, Eric L., primary, Mailankody, Sham, primary, Staehr, Mette, primary, Wang, Xiuyan, primary, Senechal, Brigitte, primary, Purdon, Terence J., primary, Daniyan, Anthony F., primary, Geyer, Mark B., primary, Goldberg, Aaron D., primary, Mead, Elena, primary, Santomasso, Bianca D., primary, Landa, Jonathan, primary, Rimner, Andreas, primary, Riviere, Isabelle, primary, Landgren, Ola, primary, and Brentjens, Renier J., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results